BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 31604539)

  • 1. Targeting the adenosine pathway for cancer immunotherapy.
    Hammami A; Allard D; Allard B; Stagg J
    Semin Immunol; 2019 Apr; 42():101304. PubMed ID: 31604539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response].
    Gros L; Paturel C; Perrot I; Bensussan A; Eliaou JF; Bastid J; Bonnefoy N
    Med Sci (Paris); 2020 Feb; 36(2):112-115. PubMed ID: 32129745
    [No Abstract]   [Full Text] [Related]  

  • 3. High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73.
    Kumar M; Lowery R; Kumar V
    SLAS Discov; 2020 Mar; 25(3):320-326. PubMed ID: 31868071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
    Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
    Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD73 and adenosine generation in the creation of regulatory microenvironments.
    Regateiro FS; Cobbold SP; Waldmann H
    Clin Exp Immunol; 2013 Jan; 171(1):1-7. PubMed ID: 23199317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cancer-derived adenosine: new therapeutic approaches.
    Young A; Mittal D; Stagg J; Smyth MJ
    Cancer Discov; 2014 Aug; 4(8):879-88. PubMed ID: 25035124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
    Allard B; Longhi MS; Robson SC; Stagg J
    Immunol Rev; 2017 Mar; 276(1):121-144. PubMed ID: 28258700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
    Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
    Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD39 and CD73 in immunity and inflammation.
    Antonioli L; Pacher P; Vizi ES; Haskó G
    Trends Mol Med; 2013 Jun; 19(6):355-67. PubMed ID: 23601906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD73 as a potential opportunity for cancer immunotherapy.
    Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
    Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints.
    Baghbani E; Noorolyai S; Shanehbandi D; Mokhtarzadeh A; Aghebati-Maleki L; Shahgoli VK; Brunetti O; Rahmani S; Shadbad MA; Baghbanzadeh A; Silvestris N; Baradaran B
    Life Sci; 2021 Oct; 282():119826. PubMed ID: 34265363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
    Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
    Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
    Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
    Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CD73 to augment cancer immunotherapy.
    Roh M; Wainwright DA; Wu JD; Wan Y; Zhang B
    Curr Opin Pharmacol; 2020 Aug; 53():66-76. PubMed ID: 32777746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?
    Shi L; Yang L; Wu Z; Xu W; Song J; Guan W
    Int Immunopharmacol; 2018 Oct; 63():58-65. PubMed ID: 30075429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the CD73-adenosine axis in immuno-oncology.
    Allard D; Chrobak P; Allard B; Messaoudi N; Stagg J
    Immunol Lett; 2019 Jan; 205():31-39. PubMed ID: 29758241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD73-adenosine: a next-generation target in immuno-oncology.
    Allard D; Allard B; Gaudreau PO; Chrobak P; Stagg J
    Immunotherapy; 2016 Feb; 8(2):145-63. PubMed ID: 26808918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxygenation and A2AR blockade to eliminate hypoxia/HIF-1α-adenosinergic immunosuppressive axis and improve cancer immunotherapy.
    Halpin-Veszeleiova K; Hatfield SM
    Curr Opin Pharmacol; 2020 Aug; 53():84-90. PubMed ID: 32841869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID.
    Sauer AV; Brigida I; Carriglio N; Hernandez RJ; Scaramuzza S; Clavenna D; Sanvito F; Poliani PL; Gagliani N; Carlucci F; Tabucchi A; Roncarolo MG; Traggiai E; Villa A; Aiuti A
    Blood; 2012 Feb; 119(6):1428-39. PubMed ID: 22184407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting adenosine and regulatory T cells in cancer immunotherapy.
    Churov A; Zhulai G
    Hum Immunol; 2021 Apr; 82(4):270-278. PubMed ID: 33610376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.